Our Vision
To improve global human health by providing broad and robust, long-term immunity for some of the world’s most pressing infectious diseases.
Gylden’s T cell-priming vaccine and immunotherapy candidates combine core proprietary technologies
- To offer broad and robust, cross-reactive protection against viruses of the same family, as well as against existing and potential variants (one product, multiple pathogen protection)
- To extend duration of immune protection, potentially for up to decades
- To enable transport and storage for extended periods of time with stability at room temperature (avoiding conventional cold chain requirements)
- To be delivered via intradermal micro-needles directly into the skin, avoiding conventional needle administration
- To be suited for rapid ‘plug and play’ development and scale-up with an ultrasmall passivated nanocluster delivery platform.
